{"symbol": "VTGN", "companyName": "VistaGen Therapeutics Inc.", "exchange": "NASDAQ Capital Market", "industry": "Biotechnology", "website": "http://www.vistagen.com", "description": "VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.", "CEO": "Shawn K. Singh", "issueType": "cs", "sector": "Healthcare", "tags": ["Healthcare", "Biotechnology"]}